Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.35 USD | -1.34% | -7.20% | -2.36% |
Financials (USD)
Sales 2024 * | 239K | Sales 2025 * | 8.8M | Capitalization | 155M |
---|---|---|---|---|---|
Net income 2024 * | -119M | Net income 2025 * | -147M | EV / Sales 2024 * | 24.7 x |
Net cash position 2024 * | 149M | Net cash position 2025 * | 136M | EV / Sales 2025 * | 2.17 x |
P/E ratio 2024 * |
-1.17
x | P/E ratio 2025 * |
-1.29
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on Adverum Biotechnologies, Inc.
1 day | -1.34% | ||
1 week | -7.20% | ||
Current month | -7.20% | ||
1 month | -28.92% | ||
3 months | -61.72% | ||
6 months | -27.23% | ||
Current year | -2.36% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Linda Rubinstein
DFI | Director of Finance/CFO | 58 | 22-12-11 |
Bill Tan
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Whitcup
BRD | Director/Board Member | 64 | 20-04-15 |
Clarence Machado
CHM | Chairman | 60 | 17-03-13 |
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 7.35 | -1.34% | 93,793 |
24-06-06 | 7.45 | -1.72% | 92,203 |
24-06-05 | 7.58 | +0.80% | 104,178 |
24-06-04 | 7.52 | -2.97% | 110,936 |
24-06-03 | 7.75 | -2.15% | 170,012 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.36% | 155M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- ADVM Stock